KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precigen (PGEN) Cash & Equivalents (2016 - 2025)

Precigen (PGEN) has disclosed Cash & Equivalents for 13 consecutive years, with $29.5 million as the latest value for Q4 2024.

  • On a quarterly basis, Cash & Equivalents rose 289.51% to $29.5 million in Q4 2024 year-over-year; TTM through Dec 2024 was $29.5 million, a 289.51% increase, with the full-year FY2024 number at $29.5 million, up 289.51% from a year prior.
  • Cash & Equivalents was $29.5 million for Q4 2024 at Precigen, up from $24.7 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $51.8 million in Q4 2020 to a low of $4.9 million in Q4 2022.
  • A 5-year average of $27.5 million and a median of $29.5 million in 2024 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: plummeted 75.84% in 2023, then surged 289.51% in 2024.
  • Precigen's Cash & Equivalents stood at $51.8 million in 2020, then fell by 19.43% to $41.7 million in 2021, then plummeted by 88.36% to $4.9 million in 2022, then soared by 55.99% to $7.6 million in 2023, then soared by 289.51% to $29.5 million in 2024.
  • Per Business Quant, the three most recent readings for PGEN's Cash & Equivalents are $29.5 million (Q4 2024), $24.7 million (Q3 2024), and $9.3 million (Q2 2024).